Evan Kearns's most recent trade in Cogent Biosciences Inc was a trade of 65,000 Common Stock done at an average price of $38.7 . Disclosure was reported to the exchange on Dec. 26, 2025.
| Stock | Client Name | Client Category | Action | Reported to Exchange | Quantity | Post Transaction Holding | Traded % | Avg. Price | Value | Security Type |
|---|---|---|---|---|---|---|---|---|---|---|
| Cogent Biosciences Inc | Evan Kearns | Chief Legal Officer | Sale of securities on an exchange or to another person at price $ 38.70 per share. | 26 Dec 2025 | 65,000 | 109,398 (0%) | 0% | 38.7 | 2,515,500 | Common Stock |
| Cogent Biosciences Inc | Evan Kearns | Chief Legal Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 17 Dec 2025 | 260,000 | 300,000 (1%) | 0% | 0 | Common Stock | |
| Cogent Biosciences Inc | Evan Kearns | Chief Legal Officer | Payment of exercise price or tax liability using portion of securities received from the company at price $ 39.45 per share. | 17 Dec 2025 | 125,602 | 174,398 (0%) | 0% | 39.5 | 4,954,999 | Common Stock |
| Cogent Biosciences Inc | Evan Kearns | Chief Legal Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 17 Dec 2025 | 55,000 | 55,000 | - | - | Stock Option (Right to Buy) | |
| Cogent Biosciences Inc | Evan Kearns | Chief Legal Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 17 Dec 2025 | 40,000 | 40,000 (0%) | 0% | 0 | Common Stock | |
| Cogent Biosciences Inc | Evan Kearns | Chief Legal Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 23 Jan 2025 | 230,000 | 230,000 | - | - | Stock Option (Right to Buy) | |
| Cogent Biosciences Inc | Evan Kearns | Chief Legal Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 23 Jan 2024 | 255,000 | 255,000 | - | - | Stock Option (Right to Buy) | |
| Cogent Biosciences Inc | Evan Kearns | Chief Legal Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 13 Feb 2023 | 140,000 | 140,000 | - | - | Stock Option (Right to Buy) | |
| Cogent Biosciences Inc | Evan Kearns | Chief Legal Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 25 Jan 2022 | 202,250 | 202,250 | - | - | Stock Option (Right to Buy) |